Click here to book your

RT-PCR SARS-Cov-2 Test (Coronatest)

100 microbial species and resistance genes in just 3 hours directly from whole blood

Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection (Sepsis-3 definition). Between 27 and 30 million septic patients are recorded annually and between 6 to 9 million of these patients die (mortality rate ~ 30%). The cost of treating sepsis is enormous: in 2008 USD 14.6 billion was spent in the US alone (with an average growth rate in cost of 11.9%). Most types of microorganisms can cause sepsis. However, the vast majority of cases is caused by bacteria and fungi. 

 

Experts strongly recommend focusing on the early identification of the sepsis-causing microorganisms to personalize and limit antimicrobial treatment to reduce life-threatening complications. If a patient receives appropriate antimicrobial therapy within the first hour of clinical diagnosis, chances of survival are close to 80%; this goes down by 7.6% for every hour of delay.

 

Cube Dx' early Pathogen Identification directly from whole blood and other sample matrices reduces time to result to 3 hours. Therefore targeted therapy can be chosen very quickly - even for patients already treated with antimicrobial agents.



Horizon2020 project SMARTDIAGNOS: Cube Dx delivers early diagnostics of sepsis pathogens

The current pandemic of the new Corona virus (SARS-Cov-2) highlights the dangers of infections and demonstrates the need for fast and reliable diagnostic tools. However, even before the Corona pandemic a more deadly threat was and is largely neglected: sepsis.

Sepsis causes more than 8 million deaths annually and is caused mainly by bacteria. The ongoing spread of antibiotic resistance puts even more pressure on the health systems. Crucial for survival and quick recovery is an early diagnosis of the causative pathogen and its possible drug resistances.

mehr lesen

Cube Dx develops highly multiplexed screening for respiratory pathogens - including SARS-Cov-2

After the development of a highly sensitive RT-PCR test for the new coronavirus SARS-Cov-2 and a lysis buffer that replaces conventional RNA extraction, Cube Dx is now preparing for the upcoming challenges of the next cold season: a broad screening for respiratory viruses and bacteria will enable physicians to rapidly stratify patients with respiratory symptoms.

mehr lesen